Background: A common belief is that one quarter to one third of all diabetes cases remain undiagnosed. However, such prevalence estimates may be overstated by epidemiologic studies that do not use confirmatory testing, as recommended by clinical diagnostic criteria.
U
nderstanding the burden of undiagnosed diabetes is critical to the evaluation and monitoring of public health efforts related to diabetes screening and diagnosis. A common belief is that one quarter to one third of diabetes cases in the United States are undiagnosed (1) (2) (3) . However, previous estimates of the proportion of total diabetes cases that are undiagnosed may be overestimated by epidemiologic studies that do not use confirmatory testing, in line with clinical diagnostic criteria (4 -6) . National estimates of undiagnosed diabetes from large epidemiologic cohorts typically have relied on a single measurement of fasting glucose, hemoglobin A 1c (HbA 1c ), or 2-hour glucose level to identify cases of undiagnosed diabetes, potentially overstating its prevalence.
Guidelines from the American Diabetes Association explicitly state that in the absence of a clear clinical diagnosis (overt symptoms of diabetes or hyperglycemic crisis), a second test, in a new blood sample, is required to confirm the diagnosis of diabetes (7) . However, 2 different tests (for example, HbA 1c and fasting glucose levels) frequently are done in the same sample, and the guidelines state that if the results of the 2 tests are above clinical thresholds, this also confirms the diagnosis (7) . This confirmatory approach to diagnosing diabetes helps decrease false-positive results (8, 9 ).
However, previous national estimates of the prevalence of undiagnosed diabetes did not use a confirmatory testing strategy. This is of particular concern, because earlier studies demonstrated high variability among the biochemical tests used to define diabetes (8) , which may substantially inflate prevalence estimates.
Thus, the objective of this study was to quantify the overall burden, trends, and risk factors of undiagnosed diabetes in the United States by using a combination of fasting glucose and HbA 1c levels, a definition of undiagnosed diabetes consistent with clinical practice guidelines.
METHODS

Study Population
The NHANES (National Health and Nutrition Examination Survey) studies are cross-sectional, complex samples of the U.S. civilian noninstitutionalized population conducted by the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC). The present study included data from NHANES III (1988 to 1994) and the continuous NHANES (1999 to 2014), the results of which are released in 2-year cycles. The NCHS institutional review board approved protocols for the conduct of NHANES, and informed consent was obtained from all participants.
To evaluate trends over time, we used data from NHANES III (n = 7385) and 4-year survey cycles from 1999 to 2014 (n = 17 045). This study population was limited to nonpregnant adults aged 20 years and older who attended the fasting morning examination and excluded 54 eligible persons with missing fasting glucose or HbA 1c values. Persons who self-reported insulin use but did not report a diabetes diagnosis also were excluded (n = 6). (12) . These shifts have been attributed to changes in assay methods and have a substantial effect on population estimates. We used previously published methods to calibrate HbA 1c values to a stable, standard distribution to align them over time, as documented in the supplement to our 2014 report (5) .
Measurement of
Plasma glucose concentrations were measured in specimens collected from participants who attended the morning fasting examination. Laboratory methods used to measure glucose levels also changed during the NHANES data collection period, and we applied regression equations recommended by the NCHS to align the plasma glucose values over time (5, 13, 14) .
Definitions of Diagnosed and Confirmed Undiagnosed Diabetes
Diagnosed diabetes was defined as a self-reported physician diagnosis of diabetes (other than during pregnancy). Confirmed undiagnosed diabetes was defined as elevated levels of both fasting glucose (≥7.0 mmol/L [≥126 mg/dL]) and HbA 1c (≥6.5%) measured in the same blood sample in a person without a previous diagnosis of diabetes. The term total diabetes is used here to refer to the combination of diagnosed and confirmed undiagnosed diabetes cases. In the main analyses, persons defined as not having diabetes included those with a single elevated fasting glucose or HbA 1c value, but not both.
We conducted sensitivity analyses comparing the prevalence of confirmed undiagnosed diabetes, defined as elevated levels of both fasting glucose and HbA 1c , with 3 definitions of unconfirmed undiagnosed diabetes (a single elevated fasting glucose value, a single elevated HbA 1c value, or either an elevated fasting glucose or an elevated HbA 1c value). We also conducted sensitivity analyses comparing risk factor prevalence and associations in persons with unconfirmed undiagnosed diabetes, defined as a single elevated HbA 1c or fasting glucose value (but not both), confirmed undiagnosed diabetes (elevation of both HbA 1c and fasting glucose levels), or diagnosed diabetes. In this sensitivity analysis, the no-diabetes group comprised persons with levels of both fasting glucose and HbA 1c below clinical thresholds (that is, an HbA 1c level <6.5% and a fasting glucose level <7.0 mmol/L [<126 mg/dL]).
Assessment of Demographics and Other Risk Factors
All measurements were conducted by trained personnel using standardized protocols. Information on age, sex, race/ethnicity, family history of diabetes, smoking status, education, income, history of prediabetes, health insurance status, and access to care was selfreported. Hypertension was defined as systolic blood pressure of 140 mm Hg or greater, diastolic blood pressure of 90 mm Hg or greater, or current use of blood pressure-lowering medication. High cholesterol was defined as a total cholesterol level of 240 mg/dL (6.2 mmol/L) or greater or current use of cholesterollowering medication. Body mass index (BMI) was calculated as weight in kilograms divided by height in square meters. Albumin and creatinine levels were measured in urine, and albuminuria was defined as an albumin-creatinine ratio of 30 mg/g or greater. We also evaluated metformin use by using information from the prescription medication data files. Details on the interview questions are provided in Appendix Table 1 (available at Annals.org).
Statistical Analysis
To evaluate trends over time, we calculated prevalence estimates and SEs from the 6-year cycle from NHANES III (1988 to 1994) and 4-year cycles of the continuous NHANES (1999 to 2002, 2003 to 2006, 2007 to 2010, and 2011 to 2014) . We also obtained prevalence estimates and SEs for the combined survey period from 1999 to 2014. The NCHS analytic guidelines recommend combining survey cycles to obtain more reliable estimates. Analyses were weighted to provide nationally representative estimates of the general noninstitutionalized civilian adult population of the United States. Survey weights of NHANES account for the complex survey design (including oversampling), nonresponse, and poststratification. We obtained SEs by using the Taylor series (linearization) method following analytic procedures recommended by the NCHS (15, 16). Prevalence estimates from the different survey cycles were applied to U.S. Census population numbers to obtain estimates of the number of persons with diagnosed and confirmed undiagnosed diabetes in the United States. We used predictive margins from logistic re-gression to calculate the age-, sex-, and race-adjusted prevalence ratios (PRs) for risk factors for confirmed undiagnosed diabetes, combining the most current data from 1999 to 2014. Persons with missing risk factor data were excluded from those respective analyses; covariate data were missing in less than 3% of the eligible study sample, except for the variable of family incomepoverty ratio (8% missing).
We generated a weighted scatter plot and calculated the weighted Spearman and Pearson correlations, overall percentage agreement, and percentage of positive agreement to show the concordance of fasting glucose and HbA 1c levels in the overall study sample of persons without a diabetes diagnosis. Statistical analyses were conducted by using Stata SE, version 14.2 (StataCorp). We used svy commands in Stata to account for the complex survey design of NHANES. Hemoglobin A 1c values were calibrated by using the equate package in R, version 2.15.1 (R Foundation for Statistical Computing) (5).
Role of the Funding Source
The funding source had no role in the design, conduct, or analysis of the study or the decision to submit the manuscript for publication.
RESULTS
The prevalence of total diabetes in the United States for 1999 to 2014 was 9.3%. This estimate includes an 8.1% prevalence of diagnosed diabetes and a 1.2% prevalence of confirmed undiagnosed diabetes. The prevalence of total diabetes has increased substantially, from 5.5% in 1988 to 1994 (9.7 million adults) to 10.8% in 2011 to 2014 (25.5 million adults) ( Table 1) . Confirmed undiagnosed diabetes also has increased on an absolute scale (from 0.89% in 1988 to 1994 to 1.17% in 2011 to 2014) but has decreased as a proportion of total diabetes cases during this period. When a confirmatory definition is applied, the percentage of total diabetes cases in 1988 to 1994 that were undiagnosed is 16.3%; by 2011 to 2014, this estimate had decreased to 10.9% ( Table 1) .
The distribution of population characteristics differed substantially among persons with no diabetes, those with confirmed undiagnosed diabetes, and those with diagnosed diabetes ( Table 2) . More than 90% of persons with confirmed undiagnosed diabetes were overweight or obese (BMI, ≥25 kg/m 2 ). Age, sex, and race were major risk factors for confirmed undiagnosed diabetes, with higher prevalence estimates at older ages; in men versus women; and in blacks, Mexican Americans, and Asian Americans compared with nonHispanic white adults ( Prevalence estimates based on definitions of unconfirmed undiagnosed diabetes (such as a single elevated fasting glucose or HbA 1c value) were substantially higher than those for confirmed undiagnosed diabetes (Appendix Table 2 , available at Annals.org). For example, the prevalence of undiagnosed diabetes defined by a single HbA 1c measurement of 6.5% or greater was 29% higher than that defined by the confirmatory criteria (1.48% vs. 1.15%). The prevalence of undiagnosed diabetes defined by a single fasting glucose measurement of 7.0 mmol/L (126 mg/dL) or greater was 123% higher than that defined by the confirmatory criteria (2.56% vs. 1.15%). Defining undiagnosed diabetes as an elevated level of either fasting The prevalence of diabetes risk factors tended to be higher among persons with confirmed undiagnosed diabetes than those meeting the unconfirmed definition (only 1 elevated hyperglycemia measurement) (Appendix Table 3 , available at Annals.org). For example, persons with confirmed undiagnosed diabetes were more likely than those with unconfirmed undiagnosed diabetes to be Mexican American (15% vs. 6%), to be obese (65% vs. 53%), to have no health insurance (24% vs. 12.5%), and to have not had a recent health care visit (28% vs. 7.8%). Age-, sex-, and race-adjusted risk factor associations for confirmed undiagnosed diabetes tended to be stronger than those for unconfirmed undiagnosed diabetes (Appendix Table 4 , available at Annals.org). One exception to this pattern was agepersons with confirmed undiagnosed diabetes tended to be somewhat younger than those with unconfirmed or diagnosed diabetes.
DISCUSSION
Defining undiagnosed diabetes on the basis of clinical practice guidelines suggests that the total number of U.S. adults with diabetes in 2015 was approximately 25.5 million, up from 21.4 million in 2010, with the vast majority of diabetes cases being diagnosed. The prevalence of confirmed undiagnosed diabetes in 2011 to 2014 was 1.17%, or 2.77 million adults in 2015.
Currently, CDC estimates, which do not use confirmatory testing, are that 30.1 million U.S. adults have diabetes, 23.8% (7.2 million) of whom have undiagnosed disease (2) . These data also are derived by applying NHANES estimates from 2011 to 2014 to the 2015 U.S. Census population. Using these most recent national data but requiring confirmatory testing, we found that 25.5 million U.S. adults had diabetes and that only about 11% of this population had undiagnosed disease. This difference reflects our use of a definition of undiagnosed diabetes that is in line with clinical guidelines to most accurately estimate the pro- 
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ORIGINAL RESEARCH portion of persons with undiagnosed diabetes in the United States. When confirmation is used, we see that undiagnosed diabetes is only a small fraction of total diabetes cases; this is particularly true in older adults, in whom most diabetes cases are diagnosed (only 6.7% of total diabetes cases in adults aged 65 and older were undiagnosed in 2011 to 2014). Our findings are in stark contrast to previously published national estimates and statements in current clinical practice guidelines, which suggest that one quarter to one third of diabetes cases are undiagnosed (1, 2, 6, 7). Our analysis demonstrates that we are doing a better job with diabetes screening and diagnosis than might be inferred from previous estimates; overall, only a relatively small portion of the U.S. population who would be identified clinically as having diabetes has undiagnosed disease. Further, we found that the percentage of diabetes cases that are undiagnosed has decreased over time (from 16.3% in 1988 to 1994 to 10.9% currently). This finding is consistent with increased diabetes screening and diagnosis in the United States during the past 2 decades (17). Our results may suggest that in the current stage of the U.S. diabetes epidemic, the greatest gains will be made from emphasizing highly targeted screening programs and improving management of diagnosed diabetes.
Age and BMI are by far the most important risk factors for diabetes. Current guidelines state that routine screening for diabetes should begin at age 45 years, although screening is recommended in overweight or obese adults of any age (7). Our results support current screening recommendations for targeting middle-aged and older adults, those who are overweight or obese, high-risk racial/ethnic groups (including Asian Americans), and persons with a family history of diabetes. We also found that men were more likely than women to have confirmed undiagnosed diabetes. Persons with health insurance were less likely to have confirmed undiagnosed diabetes, suggesting that expanding coverage may help ensure that diabetes does not go undiagnosed. The stronger risk factor associations for the confirmed definition of undiagnosed diabetes (compared with a single elevated hyperglycemia measurement) and evidence for low health care access and use help demonstrate the construct validity of this definition. Our findings suggest that persons with confirmed undiagnosed diabetes are a high-risk population that is being missed by our current screening programs. Of concern, more than 60% of persons with confirmed undiagnosed diabetes had an HbA 1c value greater than 7%, the "usual target" for glycemic control in adults with type 2 diabetes. We also observed that a substantial portion of younger adults (aged 20 to 45 years) with confirmed undiagnosed diabetes had very high HbA 1c levels (about 65% had an HbA 1c value ≥8%), suggesting the presence of a subgroup of overweight and obese adults who lack access to care and are being missed by current screening practices.
Earlier prevalence studies relied on conventional definitions of undiagnosed diabetes based on a single measure, thus overstating prevalence. In the presence of random error, a single biochemical measurement will always overestimate the prevalence of a condition defined above or below a cut point of that measurement in the population. We almost never conduct confirmatory testing in persons with abnormal values in large population-based studies. Thus, an inherent incongruity exists between how diabetes is diagnosed in clinical practice and how diabetes cases are identified in epidemiologic studies. Our study demonstrates that using a confirmatory definition based on a combination of fasting glucose and HbA 1c levels can help address this issue. When we directly contrasted our confirmatory definition of undiagnosed diabetes to unconfirmed definitions used widely in the literature, we observed substantial differences in prevalence. Indeed, unconfirmed definitions resulted in prevalence estimates that were 22% to more than 200% higher. The discordance 
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increased with age, suggesting a high rate of falsepositive results in older adults and thus an even greater need to use confirmatory testing in this population. This study had several limitations that should be considered when interpreting its results. First, we had information only on fasting glucose and HbA 1c levels measured in a single blood sample at 1 time point. Our results likely would differ somewhat if a second blood sample were obtained to confirm the elevations in either the fasting glucose or HbA 1c level. Indeed, our previous work examining repeated fasting glucose measurements in different blood samples collected approximately 2 weeks apart demonstrated that the prevalence of undiagnosed diabetes is overestimated by as much as 24% if only a single fasting glucose measurement is used versus confirmation with a second measurement in a new blood sample (8) .
Second, we relied on self-report to identify persons with diagnosed diabetes, which may have resulted in some misclassification.
Third, fasting glucose measurements were available only in the morning subsample of each NHANES survey, resulting in less precise estimates, particularly for subgroup analyses.
Finally, NHANES sampled only noninstitutionalized adults; therefore, our analysis probably underrepresented some segments of the population.
Since 2010, the American Diabetes Association has recommended measuring HbA 1c levels for diagnosing diabetes. Adding the HbA 1c test at a cut point of 6.5% or higher to the diabetes diagnostic criteria was justified by its high specificity (18). Using a combination of glucose and HbA 1c values from a single fasting blood sample leverages the advantages of both tests; may eliminate the need for a return patient visit for a second blood draw; and, because HbA 1c levels are used to guide treatment, allows providers to make treatment decisions based on the HbA 1c test result. In our data and those from other population-based studies, HbA 1c and fasting glucose levels are strongly correlated (19 -21) , but classification may be discordant when single measurements are used to classify diabetes. If the 2 different tests are used for diagnosis, attention should be paid to any substantial discordance, because it may indicate a sample processing problem (common for glucose measurement), the presence of anemia (which may affect the interpretation of HbA 1c values), a coexisting medical condition that may be interfering with the interpretation of the test result, or physiologic random variation.
The percentage of total diabetes cases that are undiagnosed is a critical public health indicator. Our study demonstrates the importance of using a definition of undiagnosed diabetes in epidemiologic studies that is more consistent with clinical practice to derive accurate population estimates of the burden of undiagnosed diabetes. Our results also suggest that, overall, most diabetes cases are being captured by current screening and diagnostic practices. Persons with undiagnosed diabetes are only a small fraction of the total diabetes population; most adults (about 90%) with diabetes in the United States have received a diagnosis of the condition. Further, most U.S. adults with undiagnosed diabetes are overweight or obese, suggesting the importance of regular screening in this population; particular attention should be paid to obese adults, regardless of age. Ultimately, our results should help inform the allocation of public health resources and suggest the importance of targeted screening efforts. 
